

# Pharmacy Benefits Management Workflow Modules at EHR Point of Care (PoC)

by

© Lawrence W. Abrams, Ph.D. Economist [1]

April 28, 2026

## Predicted Impact on PMPY trend and Healthcare Outcomes

- Unit prices - down due to better formulary choices, opt to alternative cash pays including direct Pharma to patient
- Quantities - up due to much better adherence
- PMPY trend - same
- Healthcare outcome - much improved due to better choice of drugs, adherence, risk assessment

## Related Work in Progress:

- Identifying Pharmacy Benefit Management agency issues at PoS vs PoC
- whether agentic AI would increase or decrease agency issues
- EHR customer choice: internal AI of EHR company or 3rd party solutions

Letter colors: Black - Point of Care (PoC) only

Red - Point of Sale (PoS) moved to PoC

Blue - Newly enabled at PoC

**Patient Visit Login** - Multiple Patient identifiers and physician NPI Identifier

## Notes

Ambient Scribe and note generator

## Insurance Verification

Verification

Coordination of Benefits

## Patient Clinical and Rx and Chart Review

Rx History

Detection of gaps in care

Risk assessment scores for diseases

## Rx Choice

### Rx Choice Recommendations

### Drug Trial Management-- Eligibility, Enrollment, Management, Rx Fill, Adherence

Real-time Prescription Benefits (RTPB) - formulary lookup, copayment estimates, prior authorization, step therapy,

### HUMIRA AND ITS BIOSIMILARS, PRICE AND PBM FORMULARY COVERAGE, 2025

Product name	Manufacturer	WAC (2024)	WAC vs. Humira	Express Scripts	CVS Caremark	Optum Rx
Humira	AbbVie	\$6,922	n.a.	-4	-5	-/√6
Humira	Cordavis <sup>7</sup> (AbbVie)	\$6,922	-0%	-	-	-
Simlandi <sup>1,2</sup>	Alvotect/Teva	\$1,038	-85%	✓	-	-
adalimumab-ryvk <sup>1,2</sup>	Quallent <sup>8</sup> (Alvotect/Teva)	\$3,750	-46%	✓	-	-
Amjevita <sup>1</sup> (High WAC)	Amgen	\$6,576	-5%	-	-	✓ <sup>3</sup>
Amjevita <sup>1</sup> (High WAC)	Nuvaila <sup>9</sup> (Amgen)	\$6,576	-5%	-	-	-
Amjevita <sup>1</sup> (Low WAC)	Amgen	\$3,115	-55%	-	-	-
Amjevita <sup>2</sup> (Low WAC)	Amgen	\$1,385	-80%	-	-	-
Amjevita <sup>2</sup> (Low WAC)	Nuvaila <sup>9</sup> (Amgen)	\$1,385	-80%	-	-	✓
Hulio	Biocon Biologics	\$6,576	-5%	-	-	-
adalimumab-fkjp	Biocon Biologics	\$995	-86%	-	-	-
Cyltezo <sup>1,2</sup>	Boehringer Ingelheim	\$6,576	-5%	✓	-	-
adalimumab-adbm <sup>1,2</sup>	Boehringer Ingelheim	\$1,315	-81%	-	-	-
adalimumab-adbm <sup>1,2</sup>	Quallent <sup>8</sup> (Boehringer Ingelheim)	\$3,750	-46%	✓	-	-
Yuflyma <sup>2</sup>	Celltrion	\$6,576	-5%	-	-	-
Yusimry <sup>2</sup>	Meitheal <sup>10</sup>	\$995	-86%	-	-	-
Idacio	Fresenius Kabi	\$6,576	-5%	-	-	-
adalimumab-aacf	Fresenius Kabi	\$899	-87%	-	-	-
Abrilada <sup>1</sup> (High WAC)	Pfizer	\$6,576	-5%	-	-	-
Abrilada <sup>1,11</sup> (Low WAC)	Pfizer	\$1,038	-85%	-	-	-
Hadlima <sup>2</sup>	Samsung Bioepis/Organon	\$1,038	-85%	-	-	-
Hyrimoz <sup>1,2</sup>	Sandoz	\$6,576	-5%	-	✓	-
Hyrimoz <sup>1,2</sup>	Cordavis <sup>7</sup> (Sandoz)	\$1,300	-81%	-	✓	-
adalimumab-adaz <sup>1,2</sup>	Sandoz	\$1,315	-81%	✓	✓	-

WAC = wholesale acquisition cost

1. Indicates product is interchangeable with Humira reference product for one or more product strength.

2. Indicates product is available in high concentration formulation.

3. Amjevita (high WAC) is on Optum Rx's Premium and Select formularies, but excluded from its Premium Value formulary. Boehringer Ingelheim's adalimumab-adbm is on the Premium Value formulary.

4. As of January 2025, Express Scripts excluded Humira for new patients. As of July 2025, Express Scripts will exclude Humira from its preferred national formulary for all utilizers.

5. In April 2024, CVS Caremark removed Humira from its major commercial formularies. The reference product remains on CVS Caremark's Choice and Standard Opt Out commercial formularies, which account for a small share of its customers and covered lives.

6. As of January 2025, Optum Rx excluded Humira from its Premium Standard formulary, but includes it on tier 3 with prior authorization on its Select Standard formulary.

7. Cordavis is a subsidiary of CVS Health, which also operates CVS Caremark. The co-branded product made by AbbVie is not a biosimilar, because it is supplied by the manufacturer of the reference product.

8. Quallent Pharmaceuticals is a subsidiary of Cigna's Evernorth business, which also operates Express Scripts.

9. Nuvaila is a subsidiary of Optum, which also operates Optum Rx. The Nuvaila products launched in 2025.

10. In 2024, Coherus divested Yusimry to Hong Kong King-Friend Industrial Co., which markets the product via its Meitheal subsidiary.

11. In August 2024, Pfizer lowered the WAC of low WAC Abrilada from \$2,769 to \$1,038 for a 28-day supply.

Source: Drug Channels Institute research. Published on *Drug Channels* ([www.DrugChannels.net](http://www.DrugChannels.net)) on January 22, 2025.

Special case: biologics with options for point of care (and related plan formulary and copayment), pharmacy:

Assisted Infusion (medical benefit plan, via specialty distributors ordered through GPOs)

- Hospital
- Physician Office
- Home

Self-injection (pharmacy benefit plan, via specialty distributors to retail and mail order pharmacies)

Medicare Part B splits biosimilar billing into two distinct components: **the drug product (HCPCS Q-code or J-code) and the method of administration (CPT administration codes)**. For 2026, CMS reinforces the use of product-specific codes for biosimilars rather than general reference biologic codes. [LinkedIn +2](#)

<b>Intravenous Infusion</b> <i>often billed via medical</i>	➤	<b>Subcutaneous* Injection</b> <i>that may now be billed via the pharmacy benefit</i>
<b>Remicade®</b> (infliximab) IV infusion is administered in infusion clinics to treat inflammatory conditions	➤	<b>Zymfentra®</b> (infliximab) subcutaneous injection form may be given by the patient or caregiver at home at the prescriber's discretion
<b>Leqembi®</b> IV infusion is administered in clinic/office settings to treat Alzheimer's	➤	<b>Leqembi IQLIK®</b> subcutaneous injection may be given by the patient or caregiver at home at the prescriber's discretion
<b>Keytruda®</b> IV infusion is administered in clinic/office settings to treat specific cancers	➤	<b>Keytruda QLEX®</b> must be administered by healthcare professionals, but injection time is much shorter and less intensive sites of care may be available
<b>Ocrevus®</b> IV infusion is administered in clinic/office settings to treat multiple sclerosis	➤	<b>Ocrevus Zunovo®</b> must be administered by healthcare professionals, but injection time is much shorter and less intensive sites of care may be available
<i>*Subcutaneous injections are administered via a small needle just under the skin. Some subcutaneous injectable products are safe for patient or caregiver administration at home.</i>		

Rx Configuration - dose, frequency, quantity and refills, special instructions

Indication Codes for coverage - (ICD-10 code)

Drug - Drug interactions alerts

Controlled Substance Documentation

Prior Authorization, reply, dispute resolution

Next StepTherapy authorization

Copayment Assistance, Accumulation, Maximizer

Physician Rx Choice (Iteration)

## Electronic Prescribing (eRx) Transmission for Fulfillment

Check patient defaults with plan networks - [estimate copays](#)

[Copay comparison with out-of-network alternatives](#)

[Re-route out of network to cash-pay retail and mail order pharmacies](#)

## The Future of Retail Rx



Drive In



TelePharmacist



Robot Deliver to Car

[Re-route to out of network cash-pay Telehealth](#)

[Re- route to direct Pharma to patient Telehealth for GLP-1, other biologics not covered by plan](#)

[Inventory Check](#)

[Route choice for biologics alternative delivery - infusions \(Hospital, out-patient clinic, home \), self-injectables \(retail pharmacy, mail order\)](#)

Choose Route and Transmit

## Rx Messaging


EHR to Patient of fill status

EHR to Pharmacy of any clarification of Rx

### Pharmacy to EHR of fill status

## Adherence

### ◆ AI Overview

Approximately 50% of patients with chronic conditions do not take their medications as prescribed, with roughly 75% of Americans struggling to follow medication instructions correctly. Poor adherence leads to 125,000 deaths, up to 25% of hospitalizations, and over \$500 billion in avoidable healthcare costs annually in the U.S.. **Optimal treatment typically requires 80% or higher adherence**, which is rarely met for long-term therapies. 

Reminder by mail order pharmacy to patient

Reminder by physician to patient after update by pharmacy

Medical device monitoring - patient to physician

## Defined Contribution Plan Management

Managed at PoC instead of plan sponsor

Copays and cashpays for Section 125 (Cafeteria Plan), HSA /FSA ,ICHRA

## Footnotes:

[1] There are no relevant disclosures pertinent to this piece. I have received no compensation or benefits from any party. I have a Ph.D. in Economics from Washington University in St. Louis and a B.A. in Economics from Amherst College.  
email: [labrams9@gmail.com](mailto:labrams9@gmail.com)